A Pilot Study to Evaluate ZADAXIN's® (Thymalfasin) Ability to Enhance Immune Response to the H1N1sw Influenza Vaccine

NCT01031966 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

120

Enrollment

INDUSTRY

Sponsor class

Conditions

END STAGE RENAL DISEASE

Interventions

BIOLOGICAL: MF59 adjuvanted H1N1 influenza monovalent vaccine
DRUG: Thymosin alpha 1
DRUG: Thymosin alpha 1

Sponsor

sigma-tau i.f.r. S.p.A.